Healthcare entity
Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention Amprius Technologies, the most common co-covered peer. Source depth averages 2 original sources per story, versus 2.5 across the same-window beat baseline.
Last mentioned: Mar 4, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention Amprius Technologies, the most common co-covered peer. Source depth averages 2 original sources per story, versus 2.5 across the same-window beat baseline. Their average consequence score of 5 runs below the beat's 5.9 for that window. We currently track 1 Healthcare story that mention Elritercept, all published on March 4, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 22 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Elritercept. Shared-story counts are live from our verified record — not editorial picks.
FY 2025 Earnings
Released full-year financial results and updated 2026 clinical guidance.
Anticipated Data
Expected top-line data readouts for multiple Phase 2 programs.
Cibotercept Progress
Initiated additional cohorts in PAH studies to evaluate dose-response.
Trial Expansion
Keros expanded the TROPOS trial to include broader MDS patient populations.
Keros Therapeutics reported its full-year 2025 results, highlighting significant clinical progress in its TGF-β protein superfamily pipeline for hematologic and cardiovascular disorders. The company maintains a robust cash position to fund pivotal trials for elritercept and cibotercept through key upcoming data readouts in 2026.
Source: lasvegassun.com · manilatimes.net
Elritercept is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
